DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder

Epigenomics

Volumn 8, Issue 2, 2016, Pages 197-208

  Houtepen, Lotte C ^a   Van Bergen, Annet H ^a   Vinkers, Christiaan H ^a   Boks, Marco P M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

antidepressant; antipsychotics; bipolar; cell type; DNA methylation; medication; mood stabilizer

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; OLANZAPINE; QUETIAPINE; VALPROIC ACID; NEUROLEPTIC AGENT; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BIPOLAR DISORDER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELLS BY BODY ANATOMY; DNA DETERMINATION; DNA METHYLATION; DRUG USE; EPIGENETICS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NERVOUS SYSTEM DEVELOPMENT; PRIORITY JOURNAL; AFFECT; BIOLOGY; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PROCEDURES; PSYCHOLOGY;

AFFECT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; TRANSCRIPTOME;

EID: 84959359344     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.98     Document Type: Article

References (82)

1. Flavell SW, Greenberg ME. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annu. Rev. Neurosci. 31, 563-590 (2008).
2. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8(5), 355-367 (2007).
3. Mill J, Tang T, Kaminsky Z et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 82(3), 696-711 (2008).
4. Dempster EL, Pidsley R, Schalkwyk LC et al. Diseaseassociated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 20(24), 4786-4796 (2011).
5. Wong CC, Meaburn EL, Ronald A et al. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. Mol. Psychiatry 19(4), 495-503 (2014).
6. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447(7143), 425-432 (2007).
7. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9(6), 465-476 (2008).
8. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 321(6067), 209-213 (1986).
9. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006).
10. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002).
11. Boks MP, Derks EM, Weisenberger DJ et al. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS ONE 4(8), e6767 (2009).
12. van Eijk KR, de JS, Boks MP et al. Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. BMC Genomics 13, 636 (2012).
13. Schubeler D. Function and information content of DNA methylation. Nature 517(7534), 321-326 (2015).
14. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cell Mol. Life Sci. 66(4), 596-612 (2009).
15. Kofink D, Boks MP, Timmers HT, Kas MJ. Epigenetic dynamics in psychiatric disorders: environmental programming of neurodevelopmental processes. Neurosci. Biobehav. Rev. 37(5), 831-845 (2013).
16. Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr. Bull. 35(6), 1045-1056 (2009).
17. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad. Sci. USA 105(44), 17046-17049 (2008).
18. Bjornsson HT, Sigurdsson MI, Fallin MD et al. Intraindividual change over time in DNA methylation with familial clustering. JAMA 299(24), 2877-2883 (2008).
19. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006).
20. Boks MP, de Jong NM, Kas MJ et al. Current status and future prospects for epigenetic psychopharmacology. Epigenetics 7(1), 20-28 (2012).
21. Grayson DR, Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 38(1), 138-166 (2013).
22. Roth TL, Sweatt JD. Regulation of chromatin structure in memory formation. Curr. Opin. Neurobiol. 19(3), 336-342 (2009).
23. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 44(3), 213-235 (2005).
24. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 23(4), 346-388 (2009).
25. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 83(Suppl. 1), S91-S92 (2004).
26. Tremolizzo L, Doueiri MS, Dong E et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol. Psychiatry 57(5), 500-509 (2005).
27. Matrisciano F, Tueting P, Dalal I et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 68, 184-194 (2013).
28. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci. 30(2), 55-60 (2009).
29. Veldic M, Kadriu B, Maloku E et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr. Res. 91(1-3), 51-61 (2007).
30. Li J, Guo Y, Schroeder FA et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J. Neurochem. 90(5), 1117-1131 (2004).
31. Matrisciano F, Dong E, Gavin DP, Nicoletti F, Guidotti A. Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Mol. Pharmacol. 80(1), 174-182 (2011).
32. Dong E, Grayson DR, Guidotti A, Costa E. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics. 1(1), 201-211 (2009).
33. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl Acad. Sci. USA 105(36), 13614-13619 (2008).
34. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14(1), 51-59 (2009).
35. Sun YV, Turner ST, Smith JA et al. Comparison of the DNA methylation profiles of human peripheral blood cells and transformed B-lymphocytes. Hum. Genet. 127(6), 651-658 (2010).
36. Lam LL, Emberly E, Fraser HB et al. Factors underlying variable DNA methylation in a human community cohort. Proc. Natl Acad. Sci. USA 109(Suppl. 2), 17253-17260 (2012).
37. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 49(8), 615-623 (1992).
38. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, patient edition with psychotic screen (SCID-I/P W/PSY SCREEN) (2002). www.scid4.org
39. Schalkwyk LC, Pidsley R, Wong CCY et al. wateRmelon: Illumina 450 methylation array normalization and metrics. (2013).
40. Chen YA, Lemire M, Choufani S et al. Discovery of crossreactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8(2), 203-209 (2013).
41. Barfield RT, Almli LM, Kilaru V et al. Accounting for population stratification in DNA methylation studies. Genet. Epidemiol. 38(3), 231-241 (2014).
42. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8(1), 118-127 (2007).
43. Houseman EA, Accomando WP, Koestler DC et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 13, 86 (2012).
44. Aryee MJ, Jaffe AE, Corrada-Bravo H et al. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30(10), 1363-1369 (2014).
45. Reinius LE, Acevedo N, Joerink M et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS ONE 7(7), e41361 (2012).
46. R Core Team. R: A language and environment for statistical computing (2014). www.gbif.org
47. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
48. Du P, Zhang X, Huang CC et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
49. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).
50. Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical clustering. J. Stat. Softw. 46(11), pii: i11 (2012).
51. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R package for causal mediation analysis. J. Stat. Softw. 59(5), 1-38 (2014).
52. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 23(2), 257-258 (2007).
53. Mitchell CP, Chen Y, Kundakovic M, Costa E, Grayson DR. Histone deacetylase inhibitors decrease reelin promoter methylation in vitro. J. Neurochem. 93(2), 483-492 (2005).
54. Dong E, Guidotti A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc. Natl Acad. Sci. USA 104(11), 4676-4681 (2007).
55. Perisic T, Zimmermann N, Kirmeier T et al. Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology 35(3), 792-805 (2010).
56. Kim B, Rincon Castro LM, Jawed S, Niles LP. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur. J. Pharmacol. 589(1-3), 45-48 (2008).
57. Popkie AP, Zeidner LC, Albrecht AM et al. Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J. Biol. Chem. 285(53), 41337-41347 (2010).
58. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 28(10), 2576-2588 (2008).
59. Fukuchi M, Nii T, Ishimaru N et al. Valproic acid induces up-or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci. Res. 65(1), 35-43 (2009).
60. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogenactivated protein kinases and promotes neurite growth. J. Biol. Chem. 276(34), 31674-31683 (2001).
61. Hao Y, Creson T, Zhang L et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24(29), 6590-6599 (2004).
62. Reus GZ, Fries GR, Stertz L et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300, 141-154 (2015).
63. Watkins CC, Sawa A, Pomper MG. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl. Psychiatry 4, e350 (2014).
64. Bian Q, Kato T, Monji A et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(1), 42-48 (2008).
65. Jaehne EJ, Corrigan F, Toben C, Jawahar MC, Baune BT. The effect of the antipsychotic drug quetiapine and its metabolite norquetiapine on acute inflammation, memory and anhedonia. Pharmacol. Biochem. Behav. 135, 136-144 (2015).
66. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 1063(1), 32-39 (2005).
67. Borsini A, Zunszain PA, Thuret S, Pariante CM. The role of inflammatory cytokines as key modulators of neurogenesis. Trends Neurosci. 38(3), 145-157 (2015).
68. Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Curr. Opin. Neurobiol. 30, 51-58 (2015).
69. Serretti A, Mandelli L. The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. Mol. Psychiatry 13(8), 742-771 (2008).
70. Horiuchi Y, Nakayama J, Ishiguro H et al. Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders. Biol. Psychiatry 55(1), 40-45 (2004).
71. Houseman EA, Kim S, Kelsey KT, Wiencke JK. DNA Methylation in Whole Blood: Uses and Challenges. Curr. Environ. Health Rep. 2(2), 145-154 (2015).
72. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. 23(Suppl. 1), 27-41 (2008).
73. Oyesanmi O, Kunkel EJ, Monti DA, Field HL. Hematologic side effects of psychotropics. Psychosomatics 40(5), 414-421 (1999).
74. Vasudev K, Keown P, Gibb I, McAllister-Williams RH. Hematological effects of valproate in psychiatric patients: what are the risk factors? J. Clin. Psychopharmacol. 30(3), 282-285 (2010).
75. Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics 48(6), 530-531 (2007).
76. Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann. Pharmacother. 39(7-8), 1346-1348 (2005).
77. Chen Q, Ouyang DY, Geng M et al. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J. Immunotoxicol. 8(3), 210-218 (2011).
78. Davies MN, Volta M, Pidsley R et al. Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol. 13(6), R43 (2012).
79. Walton E, Hass J, Liu J et al. Correspondence of DNA Methylation Between Blood and Brain Tissue and its Application to Schizophrenia Research. Schizophr. Bull. doi:10.1093/schbul/sbv074 (2015) (Epub ahead of print).
80. Illingworth RS, Gruenewald-Schneider U, De SD et al. Inter-individual variability contrasts with regional homogeneity in the human brain DNA methylome. Nucleic Acids Res. 43(2), 732-744 (2015).
81. Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(3), 559-576 (2004).
82. Aberg KA, Xie LY, McClay JL et al. Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions. Epigenomics 5(4), 367-377 (2013).